Articles > SPIMACO Q1-26 Financial Results
SPIMACO Q1-26 Financial Results
By KlickAnalytics Data Insights | May 4, 2026 04:04AM ET
- Net profits reach SAR 65.10 million in Q1-26
- Revenues drop to SAR 423.80 million, down 12.58% YoY
- Earnings per share decrease to SAR 0.52 in Q1-26
In the first quarter of 2026, Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) reported net profits of SAR 65.10 million, showing an 8.05% decrease from the previous year's SAR 70.80 million. The revenues for the same period totaled SAR 423.80 million, marking a 12.58% decline from SAR 484.80 million in the previous year.
Earnings per share (EPS) also saw a decrease, dropping to SAR 0.52 in Q1-26 from SAR 0.59 in the same period the year before. On a quarter-on-quarter basis, the profits in Q1-26 increased by 67.78% from SAR 38.80 million in Q4-25, along with a 4.43% increase in revenues from SAR 405.80 million. Additionally, SPIMACO ended 2025 with a significant YoY increase in net profits, reaching SAR 184.40 million compared to SAR 24.50 million in the previous year.
Overall, SPIMACO's financial results for Q1-26 show a mixed performance in terms of profits and revenues, indicating a challenging year ahead for the pharmaceutical company. Investors will be closely monitoring future quarterly reports to assess the company's financial health and growth prospects.
- Revenues drop to SAR 423.80 million, down 12.58% YoY
- Earnings per share decrease to SAR 0.52 in Q1-26
In the first quarter of 2026, Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) reported net profits of SAR 65.10 million, showing an 8.05% decrease from the previous year's SAR 70.80 million. The revenues for the same period totaled SAR 423.80 million, marking a 12.58% decline from SAR 484.80 million in the previous year.
Earnings per share (EPS) also saw a decrease, dropping to SAR 0.52 in Q1-26 from SAR 0.59 in the same period the year before. On a quarter-on-quarter basis, the profits in Q1-26 increased by 67.78% from SAR 38.80 million in Q4-25, along with a 4.43% increase in revenues from SAR 405.80 million. Additionally, SPIMACO ended 2025 with a significant YoY increase in net profits, reaching SAR 184.40 million compared to SAR 24.50 million in the previous year.
Overall, SPIMACO's financial results for Q1-26 show a mixed performance in terms of profits and revenues, indicating a challenging year ahead for the pharmaceutical company. Investors will be closely monitoring future quarterly reports to assess the company's financial health and growth prospects.
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.